The global tuberculous meningitis treatment market garnered a market value of USD 150 Billion in 2023 and is expected to accumulate a market value of USD 300 Billion by registering a CAGR of 7.2% in the forecast period 2023 to 2033.
Rising tuberculous meningitis incidences and the rising need for novel diagnostic technologies for precise diagnosis are projected to boost the growth of the tuberculous meningitis treatment market. Growing demand for point-of-care (PoC) services is expected to boost market expansion in the future years since PoC services give high-accuracy results in less time than traditional techniques.
Tuberculous meningitis, widely known as TB meningitis or tubercular meningitis, is a kind of bacterial meningitis caused by Mycobacterium tuberculosis infection of the meninges (the membranes that surround the central nervous system). The primary symptoms are fever and headache; disorientation appears later, and coma has a terrible prognosis. Meningism is missing in one-fifth of TB meningitis patients. Patients may experience localized neurological impairments as well.
The predominant characteristic is Mycobacterium tuberculosis of the meninges, with inflammation concentrated at the base of the brain. Cranial nerve roots may be impacted when inflammation occurs in the brain stem subarachnoid region. The symptoms will be similar to those of lesions that occupy space.
Blood-borne transmission occurs, probably by crossing the blood-brain barrier; nevertheless, a proportion of patients may acquire TB meningitis through a cortical focus rupture in the brain an even smaller proportion gets it via a bone focus rupture in the spine. Isoniazid, rifampicin, pyrazinamide, and ethambutol are used to treat TB meningitis for two months, followed by isoniazid and rifampicin alone for ten months. Steroids help minimize the chance of mortality in people who do not have HIV.
During the first six weeks of therapy, steroids can be administered. Some persons may require immunomodulatory drugs like thalidomide. About one-third of persons with TB meningitis develop hydrocephalus as a consequence. Aspirin may decrease or postpone death, presumably by lowering complications such as infarcts. The expanding elderly population, which is contributing to an increase in incidences of meningitis, is expected to fuel market demand.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | USD 150 Billion |
| Anticipated Forecast Value (2033) | USD 300 Billion |
| Projected Growth Rate (2023 to 2033) | 7.2% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for tuberculous meningitis treatment is projected to increase at a CAGR of 7.2% during the forecast period between 2023 and 2033, reaching a total of USD 300 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 6.4%.
In the future years, the growing need for point-of-care services is expected to fuel expansion in the worldwide tuberculous meningitis treatment market. When compared to traditional meningitis diagnostic testing procedures, point-of-care services provide more exact findings in less time.
Increased tuberculous meningitis prevalence is expected to boost growth in the worldwide market in the near future. However, the presence of a complicated and demanding regulatory environment may impede the growth of the worldwide tuberculous meningitis treatment market in the future years.
Tuberculous Meningitis Treatment Industry will be Driven by Technological Advancements to Battle Infectious Illnesses
The collaboration of the public and private sectors to enhance vaccine access to the populace is a major driving force for the expansion of the tuberculous meningitis treatment market. For example, the Global Alliance for Vaccines and Immunization (GAVIs) is an international organization that brings together the public and commercial sectors with the purpose of providing children in the world's poorest nations with access to all the newest vaccines. People with immune-compromised conditions such as HIV, cancer, diabetes, and organ transplants are more likely to get aseptic meningitis.
Advances in diagnostics and technology platforms have contributed to the expansion of the tuberculous meningitis treatment industry. For example, in 2009, Cadila formed a partnership with Novavax, a vaccine business located in the USA, to research and manufacture therapeutic and preventative vaccines to battle infectious illnesses. The introduction of a new vaccine with an enhanced mechanism, as well as advances in genetics and immunology, are projected to drive the tuberculous meningitis treatment industry forward.
High Cost of the Treatment to Stifle Market Growth
Stringent regulatory laws, as well as traditional religious views in several major market nations, are creating substantial barriers to worldwide tuberculous meningitis treatment market expansion. The intricate nature of the therapy and the high cost connected with it limits the market for tuberculous meningitis treatment.
Principal Consultant
Increasing Prevalence of Tuberculous Meningitis to Widening Profit Margins
According to the World Health Organization, Asia Pacific was the main market for tuberculous meningitis treatment in 2016 due to reasons such as increased tuberculosis meningitis prevalence. Due to the enormous population bases in some of the region's main nations, such as India and China, the Asia Pacific worldwide tuberculous meningitis treatment market is expected to rise at the fastest rate over the projected period.
Increased patient awareness as well as the development of laboratory infrastructure in the area is projected to support Asia Pacific's growth in the worldwide market in the near future. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 6.5% in the assessment period 2023 to 2033.
A Dynamic Reimbursement Landscape to Drive Market Growth
Throughout the projection period of 2023 to 2033, North America will be the quickest market for tuberculous meningitis treatment. The Centers for Disease Control and Prevention reported 9,421 TB cases in 2014, with a rate of 2.96 infections per 100,000 people.
The increased prevalence of tuberculous meningitis, a dynamic reimbursement landscape, and sophisticated healthcare infrastructure are driving market expansion. North America is expected to grow at a CAGR of 6.9% in the assessment period 2023 to 2033.
Supporting Regulatory Approval fuelling the Market in Europe
According to the World Health Organization (WHO), 32,000 patient fatalities occurred in Europe in 2015. The incidence of tuberculous meningitis in Eastern European nations, as well as supporting regulatory approval, is driving the expansion of the tuberculous meningitis treatment industry. Thus, owing to the aforementioned reasons, Europe is expected to grow at a CAGR of 6.7% in the forecast period 2023 to 2033.
The Adjunctive Corticosteroid Therapy Segment to enhance Sales Prospects
The increasing frequency of chronic illnesses, the expanding geriatric population, and increased investment in research & development are the primary driving factors driving the expansion of the adjunctive corticosteroid therapy segment further driving the market growth.
The Hospital Segment is Gaining the Most Traction in the Market
The end-user segment is divided into hospitals, specialty clinics, and others in the tuberculous meningitis treatment market. In 2022, the hospital sector accounted for the highest proportion of the worldwide market, and this trend is anticipated to continue over the assessment period. This rise can be linked to an increase in the number of foreign hospitals with technologically advanced laboratory facilities.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key start-up players in the tuberculous meningitis treatment are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. Some specific instances of key tuberculous meningitis treatment start-ups are as follows:
Key players in the tuberculous meningitis treatment market are Pfizer, GSK, Sanofi, Novartis, Merck & Co, AstraZeneca, Biomed Pvt. Ltd, K.T.Z Company Limited, Sumitomo, and Baxter.
Recent Developments:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 150 Billion |
| Market Value in 2033 | USD 300 Billion |
| Growth Rate | CAGR of 7.2% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment, End User, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, India, Malaysia, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Pfizer Inc.; GSK Inc.; Sanofi S.A; Novartis A.G; Merck & Co.; AstraZeneca Plc.; Biomed Pvt. Ltd; K.T.Z Company Limited; Sumitomo Group; Baxter International |
| Customization | Available Upon Request |
In 2023, the demand for tuberculosis meningitis treatments could generate USD 150 billion revenue.
The global adoption of tuberculosis meningitis treatments is poised to witness 7.2% CAGR through 2033.
The adjunctive corticosteroid therapy segment garners higher revenue than other treatment types.
The market in North America may witness 6.9% CAGR until 2033.
The demand in Europe is poised to record at 6.7% CAGR through 2033.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Antibiotic Therapy 5.2. Adjunctive Corticosteroid Therapy 5.3. Neurosurgical Management 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users 6.1. Hospitals 6.2. Specialty Clinics 6.3. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. Middle East and Africa (MEA) 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. Pfizer 15.2. GSK 15.3. Sanofi 15.4. Novartis 15.5. Merck & Co 15.6. AstraZeneca 15.7. Biomed Pvt. Ltd 15.8. K.T.Z Company Limited 15.9. Sumitomo 15.10. Baxter 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Tuberculous Meningitis Treatment Market
